SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-031448
Filing Date
2024-03-14
Accepted
2024-03-14 16:04:33
Documents
13
Period of Report
2024-03-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kzr-20240314.htm   iXBRL 8-K 40006
2 EX-99.1 kzr-ex99_1.htm EX-99.1 102100
  Complete submission text file 0000950170-24-031448.txt   262267

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kzr-20240314.xsd EX-101.SCH 23930
14 EXTRACTED XBRL INSTANCE DOCUMENT kzr-20240314_htm.xml XML 4536
Mailing Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-822-5600
Kezar Life Sciences, Inc. (Filer) CIK: 0001645666 (see all company filings)

IRS No.: 473366145 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38542 | Film No.: 24749691
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)